vs
Hinge Health, Inc.（HNGE）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Hinge Health, Inc.的1.3倍（$207.3M vs $154.2M），Hinge Health, Inc.净利率更高（-1.2% vs -62.0%，领先60.8%），Hinge Health, Inc.自由现金流更多（$82.3M vs $-100.8M）
Hinge Health是全球领先的数字肌肉骨骼健康解决方案提供商，面向企业雇主、健康保险机构及个人用户，提供结合临床验证的运动疗法、疼痛管理、一对一健康指导的综合性干预服务，业务覆盖北美、欧洲等地区。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
HNGE vs RARE — 直观对比
营收规模更大
RARE
是对方的1.3倍
$154.2M
净利率更高
HNGE
高出60.8%
-62.0%
自由现金流更多
HNGE
多$183.1M
$-100.8M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $154.2M | $207.3M |
| 净利润 | $-1.8M | $-128.6M |
| 毛利率 | 81.8% | — |
| 营业利润率 | -4.0% | -54.7% |
| 净利率 | -1.2% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $-0.02 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HNGERARE
| Q4 25 | — | $207.3M | ||
| Q3 25 | $154.2M | $159.9M | ||
| Q2 25 | $139.1M | $166.5M | ||
| Q1 25 | — | $139.3M | ||
| Q4 24 | — | $164.6M | ||
| Q3 24 | — | $139.5M | ||
| Q2 24 | — | $147.0M | ||
| Q1 24 | — | $108.8M |
净利润HNGERARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $-1.8M | $-180.4M | ||
| Q2 25 | $-575.7M | $-115.0M | ||
| Q1 25 | — | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | — | $-133.5M | ||
| Q2 24 | — | $-131.6M | ||
| Q1 24 | — | $-170.7M |
毛利率HNGERARE
| Q4 25 | — | — | ||
| Q3 25 | 81.8% | — | ||
| Q2 25 | 70.3% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率HNGERARE
| Q4 25 | — | -54.7% | ||
| Q3 25 | -4.0% | -106.9% | ||
| Q2 25 | -417.5% | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% | ||
| Q1 24 | — | -151.9% |
净利率HNGERARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | -1.2% | -112.8% | ||
| Q2 25 | -413.8% | -69.0% | ||
| Q1 25 | — | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | — | -95.7% | ||
| Q2 24 | — | -89.5% | ||
| Q1 24 | — | -156.8% |
每股收益（稀释后）HNGERARE
| Q4 25 | — | $-1.28 | ||
| Q3 25 | $-0.02 | $-1.81 | ||
| Q2 25 | $-13.10 | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $480.0M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $208.0M | $-80.0M |
| 总资产 | $769.8M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HNGERARE
| Q4 25 | — | $421.0M | ||
| Q3 25 | $480.0M | $202.5M | ||
| Q2 25 | $413.3M | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
股东权益HNGERARE
| Q4 25 | — | $-80.0M | ||
| Q3 25 | $208.0M | $9.2M | ||
| Q2 25 | $173.8M | $151.3M | ||
| Q1 25 | — | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | — | $346.8M | ||
| Q2 24 | — | $432.4M | ||
| Q1 24 | — | $140.3M |
总资产HNGERARE
| Q4 25 | — | $1.5B | ||
| Q3 25 | $769.8M | $1.2B | ||
| Q2 25 | $693.7M | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $82.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $82.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | 53.4% | -48.6% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流HNGERARE
| Q4 25 | — | $-99.8M | ||
| Q3 25 | $82.4M | $-91.4M | ||
| Q2 25 | $25.1M | $-108.3M | ||
| Q1 25 | — | $-166.5M | ||
| Q4 24 | — | $-79.3M | ||
| Q3 24 | — | $-67.0M | ||
| Q2 24 | — | $-77.0M | ||
| Q1 24 | — | $-190.7M |
自由现金流HNGERARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | $82.3M | $-92.7M | ||
| Q2 25 | $24.9M | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率HNGERARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | 53.4% | -58.0% | ||
| Q2 25 | 17.9% | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度HNGERARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HNGE
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
